Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
46.31
+1.26 (2.80%)
May 2, 2024, 12:03 PM EDT - Market open
Crinetics Pharmaceuticals Employees
Crinetics Pharmaceuticals had 290 employees on December 31, 2023. The number of employees increased by 80 or 38.10% compared to the previous year.
Employees
290
Change (1Y)
80
Growth (1Y)
38.10%
Revenue / Employee
$13,838
Profits / Employee
-$739,755
Market Cap
3.62B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 290 | 80 | 38.10% |
Dec 31, 2022 | 210 | 67 | 46.85% |
Dec 31, 2021 | 143 | 50 | 53.76% |
Dec 31, 2020 | 93 | 25 | 36.76% |
Dec 31, 2019 | 68 | 21 | 44.68% |
Dec 31, 2018 | 47 | 13 | 38.24% |
Dec 31, 2017 | 34 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Envista Holdings | 12,800 |
RadNet | 7,872 |
Oscar Health | 2,400 |
iRhythm Technologies | 2,000 |
10x Genomics | 1,259 |
Axonics | 797 |
Prestige Consumer Healthcare | 560 |
Iovance Biotherapeutics | 557 |
CRNX News
- 20 days ago - Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study - Reuters
- 6 weeks ago - Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients - GlobeNewsWire
- 7 weeks ago - Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome - GlobeNewsWire
- 7 weeks ago - Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 - GlobeNewsWire